Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinson's disease

Biochemical Pharmacology

Volumn 70, Issue 9, 2005, Pages 1371-1381

  Liang, Qinghua ^a   Smith, Amanda D ^a   Pan, Stephen ^a   Tyurin, Vladimir A ^b   Kagan, Valerian E ^b   Hastings, Teresa G ^a   Schor, Nina Felice ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Antioxidants; Autonomic nervous system; Dopamine; Neuroprotection; Parkinson's disease; Reactive oxygen species

Indexed keywords

ALBUMIN; ANTIOXIDANT; DEXAMPHETAMINE; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN; TEMPOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTONOMIC DYSFUNCTION; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CIRCLING BEHAVIOR; CORPUS STRIATUM; DISEASE ASSOCIATION; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; MESENCEPHALON; METABOLITE; MORTALITY; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PTOSIS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; AUTONOMIC NERVOUS SYSTEM; CELL LINE; CELL SURVIVAL; CORPUS STRIATUM; CYCLIC N-OXIDES; DOPAMINE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NF-KAPPA B; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEPTIDE NUCLEIC ACIDS; REACTIVE OXYGEN SPECIES; SPIN LABELS; SUBSTANTIA NIGRA;

EID: 25644445936     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.04.011     Document Type: Article

References (59)

1. J. Jankovic, M. Stacy, and Movement Disorders C.G. Goetz E.J. Pappert Textbook of clinical neurology 1999 WB Saunders Company Philadelphia 655 656
2. Y. Niimi, T. Ieda, M. Hirayama, Y. Koike, G. Sobue, and Y. Hasegawa Clinical and physiological characteristics of autonomic failure with Parkinson's disease Clin Autonom Res 9 1999 139 144
3. J. Han, F.C. Cheng, Z. Yang, and G. Dryhurst Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease J Neurochem 73 1999 1683 1695
4. A.M. Bonnet, and J.L. Houeto Pathophysiology of Parkinson's disease Biomed Pharmacother 53 1999 117 121
5. J. Zhang, G. Perry, M.A. Smith, D. Robertson, S.J. Olson, and D.G. Graham Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons Am J Pathol 154 1999 1423 1429
6. M. Martinez, N. Martinez, A.I. Hernandez, and M.L. Ferrandiz Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci 64 1999 1253 1257
7. J.P. Spencer, P. Jenner, S.E. Daniel, A.J. Lees, D.C. Marsden, and B. Halliwell Conjugates of cathecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species J Neurochem 71 1998 2112 2122
8. M. Merad-Boudia, A. Nicole, D. Santiard-Baron, C. Sallie, and I. Ceballos-Picot Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease Biochem Pharmacol 56 1998 645 655
9. M.J. Aminoff Treatment of Parkinson's disease West J Med 161 1994 303 308
10. I. Shoulson DATATOP: a decade of neuroprotective inquiry Ann Neurol 44 3 Suppl. 1 1998 S160 S166
11. A.H.V. Shapira, and W.C. Olanow Neuroprotection in Parkinson's disease: mysteries, myths, and misconceptions JAMA 291 2004 358 364
12. C.A. Hubel, V.E. Kagan, E.R. Kisin, M.K. McLaughlin, and J.M. Roberts Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implications for oxidative stress Free Radic Biol Med 23 1997 596 609
13. P. Kuppusamy, P. Wang, J.L. Zweier, M.C. Krishna, J.B. Mitchell, and L. Ma Electron paramagnetic resonance imaging of rat heart with nitroxide and polynitroxyl-albumin Biochemistry 35 1996 7051 7057
14. A. Weinberg, K.D. Nylander, C. Yan, L. Ma, C.J. Hsia, and V.A. Tyruin Prevention of catecholaminergic oxidative toxicity by 4-hydroxy-2,2,6,6- tetramethylpiperidine-1-oxyl and its recycling complex with polynitroxylated albumin, TEMPOL/PNA Brain Res 1012 2004 13 21
15. P. Jenner, and C.W. Olanow Oxidative stress and the pathogenesis of Parkinson's disease Neurology 47 6 Suppl. 3 1996 S161 S170
16. A. Samuni, C.M. Krishna, J.B. Mitchell, C.R. Collins, and A. Russo Superoxide reaction with nitroxides Free Radic Res Commun 9 1990 241 249
17. J. Chateauneuf, J. Lusztyk, and K.U. Ingold Absolute rate constants for the reactions of some carbon-centered radicals with 2,2,6,6- tetramethylpiperidine-N-oxyl J Org Chem 53 1988 1629 1632
18. A. Samuni, J.B. Mitchell, W. DeGraff, C.M. Krishna, U. Samuni, and A. Russo Nitroxide SOD-mimics: modes of action Free Radic Res Commun 12/13 1991 187 194
19. A. Samuni, D. Winkelsberg, A. Pinson, S.M. Hahn, J.B. Mitchell, and A. Russo Nitroxide stable radicals protect beating cardiomyocytes against oxidative damage J Clin Invest 87 1991 1526 1530
20. P. Purpura, L. Westman, P. Will, A. Eidelman, V.E. Kagan, and A.N. Osipov Adjunctive treatment of murine neuroblastoma with 6-hydroxydopamine Cancer Res 56 1996 2336 2342
21. C. Yan, Y. Liang, K.D. Nylander, J. Wong, R.M. Rudavsky, and H.U. Saragovi p75-NGF as an antiapoptotic complex: independence vs. cooperativity Mol Pharmacol 61 2002 710 719
22. G. Paxinos, and K.B.J. Franklin The mouse brain in stereotaxic coordinates 2000 Academic Press NY
23. 3H]dopamine: impact of ascorbic acid and glutathione J Neurochem 63 1994 1126 1132
24. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol Dis 10 2002 165 186
25. N.F. Schor Adjunctive use of Ethiofos (WR-2721) with free radical-generating chemotherapeutic agents in mice: new caveats for therapy Cancer Res 47 1987 5411 5414
26. T.G. Hastings, D.A. Lewis, and M.J. Zigmond Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections Proc Natl Acad Sci USA 93 1996 1956 1961
27. T.G. Hastings, and M.J. Zigmond Loss of dopaminergic neurons in Parkinsonism: possible role of reactive dopamine metabolites J Neural Transm Suppl 49 1997 103 110
28. T.L. Perry, D.V. Godin, and S. Hansen Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33 1982 305 310
29. T.L. Perry, and V.W. Yong Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients Neurosci Lett 67 1986 269 274
30. K. Winkler-Stuck, F.R. Wiedemann, C.W. Wallesch, and W.S. Kunz Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients J Neurol Sci 220 2004 41 48
31. V. Calabrese, D. Boyd-Kimball, G. Scapagnini, and D.A. Butterfield Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes In Vivo 18 2004 245 267
32. S. Shavali, E.C. Carlson, J.C. Swinscoe, and M. Ebadi 1-Benzyl-1,2,3,4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells J Neurosci Res 76 2004 563 571
33. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J Biol Chem 279 2004 26846 26857
34. H. Sawada, M. Ibi, T. Khara, M. Urushitani, A. Akaike, and S. Shimohama Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death J Neurosci Res 54 1998 707 719
35. C.W. Shults, R.H. Haas, and M.F. Beal A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease Biofactors 9 1999 267 272
36. G.G. Borisenko, V.E. Kagan, C.J.C. Hsia, and N.F. Schor Interaction between 6-hydroxydopamine and transferrin: "Let my iron go" Biochemistry 39 2000 3392 3400
37. P.E. Steele, P.H. Tang, A.J. DeGrauw, and M.V. Miles Clinical laboratory monitoring of coenzyme Q10 use in neurological and muscular diseases Am J Clin Pathol 121 Suppl. 2004 113 120
38. C.W. Shults, M.F. Beal, D. Song, and D. Fontaine Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease Exp Neurol 188 2004 491 494
39. J. Leon, D. Acuna-Castroviejo, R.M. Sainz, J.C. Mayo, D.X. Tan, and R.J. Reiter Melatonin and mitochondrial function Life Sci 75 2004 709 765
40. S.W. Park, S.H. Kim, K.H. Park, S.D. Kim, J.Y. Kim, and S.Y. Baek Preventive effect of antioxidants in MPTP-induced mouse models of Parkinson's disease Neurosci Lett 363 2004 243 246
41. R.A. Gonzalez-Polo, G. Soler, A. Rodriguezmartin, J.M. Moran, and J.M. Fuentes Protection against MPP+ neurotoxicity in cerebellar granule cells by antioxidants Cell Biol Int 28 2004 373 380
42. K.P. Datla, R.D. Bennett, V. Zbarsky, B. Ke, Y.F. Liang, and T. Higa The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease J Pharm Pharmacol 56 2004 649 654
43. M.F. Molina-Jimenez, M.I. Sanchez-Reus, D. Andres, M. Cascales, and J. Benedi Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells Brain Res 1009 2004 9 16
44. A.M. Munoz, P. Rey, R. Soto-Otero, M.J. Guerra, and J.L. Labandeira-Garcia Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration J Neurosci Res 76 2004 551 562
45. G.R. Breese, and T.D. Traylor Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons J Pharmacol Exp Ther 174 1970 413 420
46. G.R. Breese, and T.D. Traylor Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine Br J Pharmacol 44 1972 210 222
47. F. Karoum, S.J. Chrapusta, M.F. Egan, and R.J. Wyatt Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study J Neurochem 61 1993 1369 1375
48. R. Heikkila, and G. Cohen Further studies on the generation of hydrogen peroxide by 6-hydroxydopamine. Potentiation by ascorbic acid Mol Pharmacol 8 1972 241 248
49. G. Seitz, H.B. Stegmann, H.H. Jager, H.M. Schlude, H. Wolburg, and V.A. Roginsky Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine J Neurochem 75 2000 511 520
50. R. Soto-Otero, E. Mendez-Alvarez, A. Hermida-Ameijeiras, A.M. Munoz-Patino, and J.L. Labandeira-Garcia Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease J Neurochem 74 2000 1605 1612
51. K. Berger, S. Przedborski, and J.L. Cadet Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats Brain Res Bull 26 1991 301 307
52. J.L. Cadet, M. Katz, V. Jackson-Lewis, and S. Fahn Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence Brain Res 476 1991 10 15
53. M.J. Zigmond, and T.G. Hastings Neurochemical responses to lesions of dopaminergic neurons: implications for compensation and neuropathology Adv Pharmacol 42 1998 788 792
54. H. Thoenen, and J.P. Tranzer Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine Schmiedebergs Arch Exp Pathol Pharmakol 261 1968 271 288
55. T. Malmfors, and C. Sachs Degeneration of adrenergic nerves produced by 6-hydroxydopamine Eur J Pharmacol 3 1968 89 92
56. D. Blum, Y. Wu, M.-F. Nissou, S. Arnaud, A.-L. Benabid, and J.-M. Verna p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells Brain Res 751 1997 139 142
57. H. Jiang, Y. Ren, J. Zhao, and J. Feng Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis Hum Mol Genet 13 2004 1745 1754
58. A. Lilienbaum, and A. Israel From calcium to NF-kappa B signaling pathways in neurons Mol Cell Biol 23 2003 2680 2698
59. G. Chen, K.A. Bower, C. Ma, S. Fang, C.J. Thiele, and J. Luo Glycogen synthase kinase 3 beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death FASEB J 18 2004 1162 1164